News | Artificial Intelligence | April 18, 2019

Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer

FocalNet artificial neural network achieves 80.5 percent accuracy in reading MRI scans for prostate cancer, compared to 83.9 percent for experienced radiologists

Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer

April 18, 2019 — University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to help radiologists improve their ability to diagnose prostate cancer. The system, called FocalNet, helps identify and predict the aggressiveness of the disease by evaluating magnetic resonance imaging (MRI) scans, and it does so with nearly the same level of accuracy as experienced radiologists. In tests, FocalNet was 80.5 percent accurate in reading MRIs, while radiologists with at least 10 years of experience were 83.9 percent accurate.

Radiologists use MRI to detect and assess the aggressiveness of malignant prostate tumors. However, it typically takes practicing on thousands of scans to learn how to accurately determine whether a tumor is cancerous or benign, and to accurately estimate the grade of the cancer. In addition, many hospitals do not have the resources to implement the highly specialized training required for detecting cancer from MRIs.

FocalNet is an artificial neural network that uses an algorithm that comprises more than a million trainable variables; it was developed by the UCLA researchers. The team trained the system by having it analyze MRI scans of 417 men with prostate cancer; scans were fed into the system so that it could learn to assess and classify tumors in a consistent way and have it compare the results to the actual pathology specimen. Researchers compared the artificial intelligence system’s results with readings by UCLA radiologists who had more than 10 years of experience.

The research suggests that an artificial intelligence system could save time and potentially provide diagnostic guidance to less-experienced radiologists.

The study’s senior authors are Kyung Sung, assistant professor of radiology at the David Geffen School of Medicine at UCLA; Steven Raman, M.D., a UCLA clinical professor of radiology and a member of the UCLA Jonsson Comprehensive Cancer Center; and Dieter Enzmann, M.D., chair of radiology at UCLA. The lead author is Ruiming Cao, a UCLA graduate student. Other authors are Amirhossein Bajgiran, Sohrab Mirak, Sepideh Shakeri and Xinran Zhong, all from UCLA.

The research is published in IEEE Transactions on Medical Imaging,1 and was presented at the IEEE International Symposium on Biomedical Imaging (ISBI), April 8-11 in Venice, Italy, where it was selected as the runner up-for best paper.

For more information: www.ieeexplore.ieee.org

 

Reference

1. Cao R., Bajgiran A.M., Mirak S.A., et al. Joint Prostate Cancer Detection and Gleason Score Prediction in mp-MRI via FocalNet. IEEE Transactions on Medical Imaging, published online Feb. 27, 2019. DOI: 10.1109/TMI.2019.2901928

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
New Lung Ambition Alliance Aims to Double Five-year Lung Cancer Survival by 2025
News | Lung Cancer | July 17, 2019
The International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Graphic courtesy Pixabay

Graphic courtesy Pixabay

Feature | Artificial Intelligence | July 15, 2019 | By Greg Freiherr
Siemens has long focused on automation as a way to make diagnostic equipment faster and more efficient.
Videos | Artificial Intelligence | July 12, 2019
Khan Siddiqui, M.D., founder and CEO of HOPPR, discusses the economic advantages and costs presented by...